Skip to content
Search

Latest Stories

Costs and Accessibility of MSC Therapy for Parkinson’s Disease

Exploring Mesenchymal Stem Cells and Their Accessibility in Parkinson’s Disease Treatment

Parkinson’s disease is a progressive neurodegenerative disorder in which the patient has various motor symptoms. In the later Parkinson’s disease stages, the motor symptoms worsen, and the patient also develops nonmotor symptoms. 

Parkinson’s disease is believed to be caused due to the loss of dopaminergic neurons in the substantia nigra pars compacta, which is part of the basal ganglia. The loss of neurons leads to movement slowing, as seen in Parkinson’s disease. Patients with Parkinson’s disease have characteristic symptoms such as bradykinesia (slow movements), rigidity, resting tremors, walking instability, and falls. Some non-motor symptoms include expressionless faces, sleep disturbances, depression, and cognitive decline. 


Although the mechanism of Parkinson’s disease is understood to a certain extent, the current treatments only slow down the process for a bit before becoming ineffective. But with stem cells, researchers hope to change the landscape of Parkinson’s disease treatment options and hopefully provide patients with an option that not only significantly slows down disease progression but also manages to improve them.

Understanding the Financial Aspects of MSC Therapy for Parkinson’s Disease

Mesenchymal stem cell therapy is not new, but its use for Parkinson’s disease is somewhat new. It is also more costly than the normally used treatment options, oral medicines. 

MSC therapy requires a lot of steps and procedures, and to ensure the procedure's safety, a lot of money is spent on the technology. MSC is not as simple as extracting and injecting cells into the patient. Some various steps and conditions need to be taken care of. 

When the cells are extracted, whether from the patient or the donor, they must be extracted carefully and in a sterile environment. Then, they must be cultured with the appropriate growth factor before being injected into the patient. If, at any point, something goes wrong, the entire procedure fails. So, higher costs also ensure higher success rates. 

The cost is not just for the procedure but also for evaluations before and after the procedure. So, patients must spend money to get tested to ensure they are suitable candidates. After the procedure, they must follow up with the doctor regularly to ensure that everything is going to plan. All this adds to the cost, too. 

What factors determine the cost of MSC Therapy for Parkinson’s Disease?

Like any treatment option, various factors determine the cost of stem cell therapy for Parkinson’s disease. Five significant factors influence the cost of the therapy. These factors are –

  1. The type of cells used.
  2. The sourcing of the cells.
  3. The number of cells acquired.
  4. The lab in which the cells are cultured.
  5. The quality of the cells used. 

Adult stem cells, such as mesenchymal stem cells, are cheaper than embryonic stem cells, but the cost is still high. These procedures are also conducted in highly regulated and top-of-the-line labs and facilities, which further adds to the cost of the procedure. 

Unlike a simple procedure for localized pain, the injection of stem cells for Parkinson’s disease is more complex, adding to the cost. 

Does insurance cover MSC Therapy for Parkinson’s Disease treatment?

Currently, very few stem cell therapies are covered by insurance, and unfortunately, stem cell therapy for Parkinson’s disease is not one of them. However, you should consult various insurance providers to see what can be done.

How accessible is MSC Therapy for Parkinson’s Disease?

Since using stem cells to treat Parkinson’s disease is new, the therapy is not available as widely as some other stem cell therapies. It is also not available for patients at all Parkinson’s disease stages, as the results are better when treatment is undergone at an earlier stage. 

But, there are still various places conducting this treatment that can produce promising results. You can find even more information about it by consulting experts at Swiss Medica Clinics.

What are the potential financial and logistical challenges of pursuing MSC Therapy for Parkinson’s Disease?

One of the biggest hurdles from a patient’s perspective is the cost of the therapy. It is also not a simple procedure that can be done in a single day and requires a lot of testing and follow-up visits. 

Even if the cells are taken from the patient themselves, the procedures are rather complex and require a lot of technology, optimum storage, and working conditions to ensure the best results. The injection of these cells into the patient after being replicated is also a complex task and requires a lot of expertise. So, the procedure is only offered by a handful of reputable institutes. 

Affordability and Accessibility of Mesenchymal Stem Cell Therapy for Parkinson’s Disease

Neurodegenerative diseases like Parkinson’s disease can be very difficult for both the patient and their family. But with advancements in science and new treatment options like stem cell therapy, there is hope for these patients. 

Although the cost of stem cells to treat Parkinson’s disease are not minimal, the results can be rather promising. They can help improve the patient’s quality of life rather significantly. If you are in need of such a treatment, you can check out one of the most prominent clinics in this field, Swiss Medica in order to receive more information.

More For You

Rashmika Mandanna Mysaa tribal warrior

Rashmika Mandanna in her intense warrior look from Mysaa first poster

Instagram/unformulafilms

Rashmika Mandanna transforms into a tribal warrior in first solo action film 'Mysaa'

Quick highlights:

  • Rashmika Mandanna announces her next film Mysaa with a fierce first-look poster.
  • The image features Rashmika in a raw, never-seen-before warrior avatar.
  • Directed by Rawindra Pulle, the film is an emotional action thriller set in the Gond tribal world.
  • Rashmika called it her most intense role yet, saying it’s a version of herself she hadn’t met before.

Rashmika Mandanna has taken fans by surprise with the first look of her upcoming film Mysaa, revealing a fierce and gritty avatar unlike anything she’s done before. Shared on her social media, the poster hints at a powerful, raw performance, with Rashmika stepping into the shoes of a tribal warrior, a role she describes as “intense,” “unfiltered,” and “completely new.”

Keep ReadingShow less
Asda suffers nearly £600m loss as debt and IT costs surge

Asda co-ownerMohsin Issa. (Photo: Asda)

Asda suffers nearly £600m loss as debt and IT costs surge

ASDA, one of Britain’s largest supermarkets, has reported a pre-tax loss of £599 million for 2024, swinging sharply from a £180 million profit the previous year.

The loss comes despite total sales rising by over £1 billion to £26.8bn, as the retailer faces mounting debt costs, falling sales, and spiralling spending on a major IT overhaul, the Telegraph reported.

Keep ReadingShow less
starmer-getty

A total of 126 Labour MPs had publicly supported a move to block the proposals, marking the biggest rebellion under Starmer’s leadership so far. (Photo: Getty Images)

getty images

Starmer government softens welfare cuts after Labour MPs revolt

THE GOVERNMENT has backtracked on plans to reduce disability and sickness benefits following a major rebellion by MPs from within the Labour Party.

Care minister Stephen Kinnock confirmed on Friday that concessions had been made to address concerns raised by lawmakers who opposed the proposed reforms. This comes just days after prime minister Keir Starmer had said he would continue with the changes.

Keep ReadingShow less
Harshita Brella: Delhi court refuses protection for husband

Harshita Brella (Photo: Northamptonshire Police)

Harshita Brella: Delhi court refuses protection for husband

THE Delhi High Court has refused immediate relief to a man whose wife Harshita Brella was murdered in the UK, after he approached the court fearing arrest on domestic cruelty charges.

The vacation bench of justices Pratibha M Singh and Rajneesh Kumar Gupta heard the petition from Pankaj Lamba, who was challenging a magistrate's May 1 order declaring him a proclaimed offender.

Keep ReadingShow less
Jofra Archer

The 30-year-old fast bowler has struggled with injuries throughout his career and has played just 13 Tests, the last of which was in February 2021.

Getty Images

Jofra Archer recalled for second Test against India

JOFRA ARCHER has been named in England's squad for the second Test against India, marking his return to the Test side after more than four years.

The 30-year-old fast bowler has struggled with injuries throughout his career and has played just 13 Tests, the last of which was in February 2021.

Keep ReadingShow less